Insights

An expert neurologist discusses the use of targeted therapies to personalize treatment for patients with generalized myasthenia gravis (gMG) and reviews the impact on quality of life, the challenges of managing the disease, as well as new and emerging therapies.

Daniel E. Kremens, MD, JD, discusses the impact of OFF episodes on patients with Parkinson’s Disease and the current and newer strategies for managing them.

Nicholas Silvestri, MD, FAAN, discusses myasthenia gravis (MG) and generalized MG (gMG) in the treatment landscape. He reviews current and emerging treatment options and discusses the ADAPT study.

A. Gordon Smith, MD, FAAN, offers perspective on the challenges of diagnosis, new developments in therapeutics, and the need for interdisciplinary collaboration for optimal patient care.

Stuart Isaacson, MD, FAAN discusses how, why, and when OFF episodes manifest in patients with Parkinson’s Disease and highlights current treatments that are available for management of OFF episodes.

Paul Doghramji, MD, FAAFP, provides insight on the use of current treatment modalities for insomnia and the management of sleep disorders in primary care clinics.

An expert discusses the frontline management of insomnia in female patients.

Dr Kita Willams discusses the role of multidisciplinary teams in treatment and management of patients with migraine. She shares the importance of shared-decision making while managing these patients, and the importance of CGRP agents in treatment of acute and preventative migraine.

Expert neurologists review updates in the management of myasthenia gravis.

Heidi Crayton, MD, provides an update on the oral management considerations in patients with relapsing remitting multiple sclerosis.

Klaus Schmierer, MB BS, PhD, FRCP, discusses how patients with multiple sclerosis have been impacted by the COVID-19 pandemic, including guideline recommendations regarding vaccinations.

Alireza Atri, MD, PhD, discusses the many methods of testing and forming a diagnosis for patients with Alzheimer’s disease, highlighting the recent FDA approval of aducanumab and its impact.

Jeffrey L. Cummings, MD, ScD, discusses the Alzheimer’s disease and the advances recently made to improve the treatment landscape, specifically with aducanumab.

David Kudrow, MD, provides a discussion on the available treatment options for migraine management and prevention.

Expert neurologist and sleep specialist Chris Winter, MD, provides practical perspectives on the identification and management of narcolepsy and excessive daytime sleepiness.

Insight from expert neurologist Peter A. LeWitt, MD, who reviews available on-demand therapies for patients with Parkinson’s disease experiencing morning OFF episodes.

Expert neurologists discuss patient cases involving the treatment of adult-onset spinal muscular atrophy (SMA).

John Brandsema, MD, and Julie Parsons, MD, review the diagnosis and optimal management of spinal muscular atrophy.

An expert neurologist provides insight into epilepsy treatments and various factors that impact patient compliance.

Key opinion leaders in the management of relapsing/remitting multiple sclerosis, Enrique Alvarez, MD, PhD and Lawrence Steinman, MD, review key factors to consider when using high-efficacy therapies and provide an overview of emerging data for potential new treatment options.

Key opinion leaders in neurology Tanuja Chitnis, MD and Lauren B. Krupp, MD discuss the diagnosis and treatment of pediatric multiple sclerosis (MS) and provide insight into the impact that results from the PARADIGM trial of fingolimod in pediatric patients may have on the treatment landscape.

Amit Verma, MD, reviews challenging epilepsy cases and their treatment.

David Dodick, MD, and Robert Cowan, MD, FAAN, review changes to the treatment landscape for acute migraine.